BioInvent to use Merck's bioreactors to expand Swiss facility

BioInvent International AB, a Swedish company that develops novel immuno-regulatory antibodies to treat cancer, is upgrading and expanding its drug manufacturing facility with a full line of Merck’s Mobius single-use bioreactors.

BioInvent will add bioreactors of 3, 50, 200 and 1000 litres to its upstream facility in Lund, Sweden, expanding capacity and improving flexibility and scalability. Merck’s portfolio of 3 to 2000 litres single-use Mobius bioreactors offers greater flexibility & continuity for scale-up and reduces the need for re-training of operators during scale-up processes.

“Our complete portfolio of single-use technologies addresses the needs of both emerging biopharmaceutical companies and established drug developers